BidaskClub downgraded shares of Mast Therapeutics (NASDAQ:SVRA) from a strong-buy rating to a buy rating in a research report released on Tuesday morning.
SVRA has been the topic of several other research reports. Zacks Investment Research downgraded shares of Mast Therapeutics from a buy rating to a hold rating in a research note on Friday, September 15th. Ladenburg Thalmann Financial Services began coverage on shares of Mast Therapeutics in a research note on Wednesday, January 3rd. They issued a buy rating and a $35.00 target price on the stock. Roth Capital reiterated a buy rating and issued a $40.00 target price on shares of Mast Therapeutics in a research note on Wednesday, September 27th. Jefferies Group began coverage on shares of Mast Therapeutics in a research note on Friday, September 22nd. They issued a buy rating and a $20.00 target price on the stock. Finally, ValuEngine downgraded shares of Mast Therapeutics from a sell rating to a strong sell rating in a research note on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus price target of $23.58.
Shares of Mast Therapeutics (SVRA) traded down $0.47 during midday trading on Tuesday, hitting $13.33. 154,926 shares of the stock traded hands, compared to its average volume of 166,200. The company has a market capitalization of $406.57, a P/E ratio of -3.97 and a beta of 0.18. Mast Therapeutics has a 52-week low of $4.60 and a 52-week high of $17.19. The company has a current ratio of 9.15, a quick ratio of 9.15 and a debt-to-equity ratio of 0.20.
Mast Therapeutics Company Profile
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
What are top analysts saying about Mast Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Mast Therapeutics and related companies.